Transcept Announces Listing of Patent for Intermezzo; BioDelivery Announces Completion of Enrollment in Pivotal Pharmacokinetic Study Print E-mail
By Staff and Wire Reports   
Tuesday, 21 August 2012 19:25
Below is a look at some of the headlines for companies that made news in the healthcare sector on August 21, 2012.

Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT)
announced the U.S. FDA has listed U.S. Patent No. 8,242,131 (the '131 patent) in its Approved Drug Products with Therapeutic Equivalence Evaluations, or "Orange Book."

This patent, which was issued by the United States Patent and Trademark Office (USPTO) on August 14, 2012, includes claims directed to methods of treating middle-of-the-night insomnia with low doses of zolpidem. The '131 patent will expire no sooner than 2029.


=====


BioDelivery Sciences International, Inc. (Nasdaq: BDSI)
announced enrollment and the clinical portion of the pivotal pharmacokinetic study for BEMA Buprenorphine/Naloxone (BNX) for the treatment of opioid dependence has been completed.

As agreed with the U.S. FDA in February 2012, the study, referred to as BNX-103, was designed to compare the relative bioavailability of buprenorphine and naloxone from BNX with the reference product Suboxone. Meeting those requirements will represent a positive outcome of that study. All subjects have been dosed and the analytical work (i.e., plasma sample analysis) is in process. BDSI expects to report results from this pivotal pharmacokinetic study before the end of September.



Also Tuesday:



First China Pharmaceutical Group, Inc. (OTCBB: FCPG)
("First China" or the "Company"), a rapidly growing and technologically advanced pharmaceutical distribution company based in Yunnan, China, today announced its unaudited financial results for the three-month period ended June 30, 2012.

Galena Biopharma, Inc. (NASDAQ: GALE)
, a biotechnology company focused on developing innovative, targeted oncology treatments, has been invited to present at the 2012 Gateway Conference being held on September 6, 2012 at the W San Francisco Hotel.

MonsterTradingAlerts.com Is Issuing Special Free Trend Analysis Reports On The Most Active Stocks In The Market: Vision Plasma Sys (PINKSHEETS: VLNX), Applied DNA Sciences Inc. (OTCBB: APDN), Eastman Kodak Co. (PINKSHEETS: EKDKQ), Federal National Mortgage Association (OTCBB: FNMA)

TRIMEDYNE, INC. (OTCQB: TMED)
and (OTCBB: TMED) today reported its financial results for the quarter and nine months ended June 30, 2012.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter